524 related articles for article (PubMed ID: 19800535)
1. Antiangiogenic approaches to age-related macular degeneration today.
Bressler NM
Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
[TBL] [Abstract][Full Text] [Related]
2. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
3. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
4. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
[TBL] [Abstract][Full Text] [Related]
5. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
[TBL] [Abstract][Full Text] [Related]
6. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
7. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
8. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
Shah AR; Del Priore LV
Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
[TBL] [Abstract][Full Text] [Related]
10. [The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists--comments on the current therapy for neovascular AMD].
Pauleikhoff D; Bornfeld N; Gabel VP; Holz F; Roider H; ; ;
Klin Monbl Augenheilkd; 2005 May; 222(5):381-8. PubMed ID: 15912454
[TBL] [Abstract][Full Text] [Related]
11. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
12. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab: Phase III clinical trial results.
Rosenfeld PJ; Rich RM; Lalwani GA
Ophthalmol Clin North Am; 2006 Sep; 19(3):361-72. PubMed ID: 16935211
[TBL] [Abstract][Full Text] [Related]
14. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
15. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration].
Kloos P; Bernasconi P; Estermann S; Bachmann B; Rutishauser Y; Thölen A
Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378
[TBL] [Abstract][Full Text] [Related]
16. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
18. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.
Brown DM; Regillo CD
Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015
[TBL] [Abstract][Full Text] [Related]
20. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration.
Rouvas A; Liarakos VS; Theodossiadis P; Papathanassiou M; Petrou P; Ladas I; Vergados I
Ophthalmologica; 2009; 223(6):383-9. PubMed ID: 19602910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
